News

Rise in reports of pain, depression in last year of life in oncology patients


 

FROM THE ANNALS OF INTERNAL MEDICINE

References

The extent of pain, depression, and anorexia are rising in the last year of life for oncology patients, based on a survey of their family members.

Moderate or severe pain was experienced for at least a month by over 57% of 7,204 patients in their last year of life, and the incidence of pain appears to have increased between 1998 and 2010, based on data from participants who died during the longitudinal, community-based Health and Retirement study. Patients’ family members also reported that over 51% of patients experienced depression and 64% experienced anorexia in their last year of life.

The data reflect increases in the incidence of moderate to severe pain from nearly 47% in 1998-2000 to nearly 55% in 2008-2010. Increases also were noted in reports of depression and periodic confusion, researchers reported in the Feb. 2 online edition of Annals of Internal Medicine [doi:10.7326/M13-1609]). .

The researchers note other studies indicate that the intensity of treatment and the rate of adverse transitions have been increasing near the end of life. While hospice care is on the rise, it is often “tacked on” to this more intense late-life care; the median hospice stay is less than 3 weeks and such patients may not achieve symptomatic relief. Patients may not have consistent access to palliative services in outpatient, home, and long-term facility settings where most of the course of a terminal illness takes place, wrote Adam E. Singer of the Pardee RAND Graduate School, Santa Monica, Calif., and his colleagues.

The study was supported by the National Institute of Nursing Research and the Medical Scientist Training Program at the University of California.

Recommended Reading

IOM calls for pay for end-of-life planning
MDedge Hematology and Oncology
Members of Congress urge physician pay for end-of-life counseling
MDedge Hematology and Oncology
Hydrocodone rescheduling takes effect Oct. 6
MDedge Hematology and Oncology
FDA approves new abuse-prevention labeling for extended-release Embeda
MDedge Hematology and Oncology
Automated support eases hospice patient, caregiver burden
MDedge Hematology and Oncology
‘Co-rounding’ decreases patient length of stay
MDedge Hematology and Oncology
Palliative tumor removal extends survival
MDedge Hematology and Oncology
Medicare beneficiaries in hospice care get better care, have fewer costs
MDedge Hematology and Oncology
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Hematology and Oncology
NIH report on long-term opioid treatment cites lack of data, research needs
MDedge Hematology and Oncology